63.45 -0.03 (-0.05%)
After hours: 5:50PM EDT
|Bid||63.30 x 1100|
|Ask||63.59 x 1800|
|Day's Range||63.15 - 63.75|
|52 Week Range||51.72 - 82.15|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||17.39|
|Forward Dividend & Yield||2.00 (3.15%)|
|1y Target Est||N/A|
SmileDirectClub made its trading debut today. The teeth-straightening company's stock nose-diving after opening at $20.55 a share, below its IPO price of $23 per share. Yahoo Finance's Zack Guzman & Kristin Meyers, along with Webull CEO Anthony Denier discuss.
There's an intriguing case for Rite Aid (NYSE:RAD) stock at the moment. For a long time, bulls have been awaiting a turnaround that can boost Rite Aid stock, and a new CEO has finally come on board. Meanwhile, with the RAD stock price down over 95% from its early 2017 highs, the stock's valuation seems like it should be reasonable.Source: J. Michael Jones / Shutterstock.com And there is an intriguing, albeit high-risk, positive case for RAD stock at these levels.The current RAD stock price of $7.50 indicates a market cap of just under $400 million. The company's net debt (adjusted for the pending sale of two distribution centers) is over $3.2 billion. If the company's enterprise value of roughly $3.6 billion rises by just 10%, Rite Aid stock will almost double.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut I've been a longtime bear on RAD stock for reasons that go to the heart of the current bull case. The easy bull argument is that former CEO John Standley ran Rite Aid into the ground. Certainly, the revised deal with Walgreens (NASDAQ:WBA) was a massive disappointment. But the pressures on Rite Aid are the same pressures facing the rest of the industry.And so it's a bit too simplistic to believe that a new CEO can simply "fix" Rite Aid all that quickly amid the pressures on the sector. Meanwhile, the company's debt creates a major risk to Rite Aid stock going forward. Much like General Electric (NYSE:GE), a popular turnaround pick, new leadership can help RAD stock. But there are significant obstacles that add risk to the company's outlook. * 7 Momentum Stocks to Buy On the Dip Moreover, there are other ways, besides buying RAD stock, to bet on the turnaround of the sector. At the very least, those who are bullish on RAD stock should consider those options. Not Just Rite Aid's ProblemIt's important to put the performance of Rite Aid stock in the context of the pharmacy space. The entire industry is struggling right now. Fred's (NASDAQ:FRED), which was going to buy Rite Aid stores as part of the original Walgreens takeover, just filed for bankruptcy. Walgreens stock touched a five-year low last month. CVS Health (NYSE:CVS) bounced off its lowest levels in six years this spring.The RAD stock price has fallen further than other pharmacy equities. But that's because Rite Aid has more debt than its peers.In fact, since the beginning of 2018, Rite Aid stock has fallen 81%. But its enterprise value (its market cap plus the face value of its debt) is down only 22%. Over the same period, Walgreens' EV has dropped almost 20%, but its shares are down only 24%.It's clear that the entire sector is struggling with pressures. Reimbursement rates from insurance companies are falling. And sales of OTC products, perhaps due to competition from the likes of Amazon.com (NASDAQ:AMZN), remain weak.Those pressures, combined with higher fixed costs, have dragged down the sector's profits. Indeed, the operating profit of Walgreens' U.S. pharmacy business fell in the third quarter. Should Investors Buy CVS or Walgreens Instead of Rite Aid Stock?For RAD stock to finally rally, those industry pressures have to ease. But if that happens, investors can benefit by buying CVS or Walgreens instead. In terms of EV/EBITDA, Rite Aid stock is only modestly cheaper than CVS and Walgreens. As a result, investors would likely be better off buying one of the larger companies, which are big enough to muddle through if the environment doesn't improve.In an uber-bullish scenario, Rite Aid stock will no doubt outperform its peers (as it did after the financial crisis). That's because not many shares of RAD stock are available, so Rite Aid stock price can jump tremendously if its EBITDA increases and its free cash flow and net income move into the black from their current stagnation.But if the sector remains stable, Rite Aid stock will likely continue to underperform. And with $3 billion in debt due in 2023, and the company's net debt over six times its annual EBITDA, RAD may not be able to refinance.Rite Aid stock will outperform in a bullish scenario if the industry's pressures finally ease. In any other environment, Walgreens or CVS will likely do better. So investors who want to bet on the industry have to at least consider buying the shares of those larger operators instead. What Level Does the RAD Stock Price Need to Reach to Outperform Rite Aid's Bonds?There's another option to consider: Rite Aid's bonds. Like the RAD stock price, the prices of Rite Aid's bonds are at multi-year lows.The 6.125% bonds that mature in April 2023 have a current price of 79 and an annual yield to maturity of 13.7%. Longer-dated issues are potentially more attractive. The 7.7% February 2027 bonds are priced at 50, with a YTM of 21.2%.The 6.875% bonds that mature in 2028 have a similar price, with a yield to maturity of 18%.The bonds are less risky than Rite Aid stock, since secured bonds may have some value even if RAD goes bankrupt.And it's important to realize that RAD stock needs to climb substantially just to outperform those bonds. To top the April 2023 bonds, RAD stock price would need to reach $12. To beat the 2027 bonds, the RAD stock price would need to soar over 320%.The bond prices have an impact on Rite Aid stock because high demand for the bonds may cause demand for the equity to be low. And it's worth noting for near-term traders that the bond prices haven't moved lately, even as the RAD stock price has bounced 50% off its August lows. Consequently, the bonds are more attractive than they were a month ago.In the most bullish scenario, Rite Aid stock will outperform Rite Aid's debt. It will also outperform CVS, and Walgreens, and probably over 90% of the stocks in the market. The sheer size of the company's debt is why RAD stock has fallen so far - and why RAD stock can soar if it's finally able to lower its debt.But there's a long path to that bullish scenario, and some outside help is needed. And in anything less than a blue-sky outcome, investors likely will do better if they buy alternatives to Rite Aid stock.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Momentum Stocks to Buy On the Dip * 7 Dow Titans Breaking Higher * 5 Growth Stocks to Sell as Rates Move Higher The post Why Rite Aid Stock Will Probably Underperform Alternatives appeared first on InvestorPlace.
Zacks.com featured highlights include: Anixter International, CVS Health, AmerisourceBergen, AECOM and Best Buy
While the vast majority of our Ultimate Stock-Pickers are not dividend investors, a handful of them--Amana Trust Income AMANX , Columbia Dividend Income LBSAX , Oakmark Equity & Income OAKBX , and Parnassus Equity Income PRBLX --focus more heavily on income-producing stocks in their pursuit of investment return. Warren Buffett at Berkshire Hathaway BRK.B has spoken highly of companies that return capital to shareholders and is not against investing in and holding higher-yielding names, with three of Berkshire's top five holdings--wide-moat rated Wells Fargo WFC , Bank of America BAC , and Coca-Cola KO --accounting for about one third of the insurer's equity portfolio and yielding more than the S&P 500. As you may recall from previous articles, when we screen for top dividend-paying stocks among the holdings of our Ultimate Stock-Pickers, we try to find the highest-quality names that are currently held with conviction by our top managers.
Ahead of the U.S. 2020 presidential election, some investors are concerned that discussions regarding healthcare reform could take a toll on both share prices and valuations. That being said, one analyst believes that compelling investment opportunities can still be found within the managed care space. Managed care refers to various healthcare plans that try to reduce costs by controlling the type and level of services provided.Deutsche Bank’s George Hill just initiated coverage on 3 healthcare stocks, giving each a Buy rating based on their “attractive” potential for growth on September 11. Using the TipRanks Stock Comparison tool, we compared how the stocks measure up against each other based on year-to-date gain, analyst consensus as well as average analyst price target. Each of these stocks has amassed significant support from other Wall Street analysts with a “Strong Buy” analyst consensus. This is based on the last three months’ worth of ratings from the rest of the Street. Let’s dive in. CVS Health CVS Health (CVS\- Get Report) provides health plans and services under three segments that include pharmacy services, retail and long-term care as well as health care benefits. Out of the three healthcare stocks on our list, Hill cites CVS as his top pick based on its level of diversification. While shares are down 2% year-to-date, CVS has slowly but surely been working its way back up gaining 18% in the last three months. With all that the drug store and pharmacy chain has going for it, Hill sees even more growth on the way. It has about 10,000 pharmacies across the U.S. and plans to open 1,500 HealthHub stores by the end of 2021. He also highlights its integrated care delivery, which can improve beneficiary care as well as cut costs.That being said, a significant portion of its revenue is generated from its non-managed care organization (MCO) segments. CVS’ non-MCO businesses include the largest PBM, the second-largest pharmacy chain, long-term care and other services. While some investors originally expressed concerns regarding its $70 billion acquisition of health insurer Aetna in 2018, management has tried to mitigate any fears. On June 4, the company conveyed that once the two companies are fully integrated, it could see low-double digit percent earnings growth by 2022. Hill argues that the company is poised to meet its guidance based on its business strategy. “We see the company as well positioned to deliver on a vertical integration care delivery strategy, allowing the company to take share and generate positive earnings surprise. We also see the valuation of CVS shares as highly compelling and capturing potential execution and integration risks,” he explained. As a result, the three-star analyst initiated coverage with a Buy and set a $91 price target, suggesting 42% upside. All in all, the rest of the Street takes a similar position. CVS boasts a ‘Strong Buy’ analyst consensus and a $72 average price target, indicating 13% upside potential, the lowest on the list. Anthem Inc. While shares of the health insurer have slid 3% year-to-date, Hill tells investors that the dip in Anthem (ANTM\- Get Report) presents a unique buying opportunity. Recently, Anthem has attracted attention for its new PBM strategy. The company announced in March that its PBM, IngenioRX, will be more transparent and customer-friendly, with the new PBM passing along rebates to pharmacy customers. Traditional PBMs get rebate payments from drug manufacturers in exchange for placing medications on PBMs’ lists of covered drugs, or formularies. According to management, this new strategy could reduce costs and simplify services.It should be noted that IngenioRx is the product of its partnership with CVS that involves a five-year agreement signed back in 2017. CVS has its own Caremark PBM, and only processes claims and handles tasks related to prescription fulfillment for IngenioRX. Anthem has full control over clinical strategy and decides which drugs are covered. In addition to revamping its PBM strategy, its 2018 acquisitions of Aspire Health and America’s 1st Choice as well as HealthSun in 2017 are expected to drive substantial Medicare Advantage growth. Medicare Advantage plans are an alternative to original medicare that let beneficiaries choose to get their coverage through private insurance companies that contract with Medicare.While all of the above supports a strong long-term growth narrative, Hill notes that there are some risks associated with Anthem. “While execution has been strong recently, we see some implementation risk on the company’s PBM strategy, risk to the company’s Medicare Advantage growth targets, less exposure to faster-growing segments of the market and a rich relative valuation,” he stated. Nonetheless, the potential reward outweighs this risk. With his coverage initiation, Hill set a $323 price target which implies 28% upside. With 7 Buy ratings vs no Holds or Sells received in the last three months, the word on the Street is that ANTM is a ‘Strong Buy’. Its $345 average price target demonstrates the potential for 36% upside, the highest on our list. Cigna CorporationAs Cigna (CI\- Get Report) shares have declined 15% year-to-date, the Deutsche Bank analyst argues that shares are now trading at a discount. Some investors have expressed concerns that the health insurance company is overexposed in both the PBM and commercial business space. In December 2018, CI finalized its $67 billion merger with PBM Express Scripts in order to expand its reach within the sector. The merger could be a problem for CI as regulations have been proposed that would impair the PBM business model. This poses a major threat to CI as its primary non-MCO revenue comes from large PBMs. While no legislation has been passed yet, there is always a possibility that this could change. A significant portion of CI’s revenue is also generated from its commercial products. The commercial MCO space includes risk-bearing insurance and administrative services only (ASO). Hill states that while this space can be more profitable, it is slower growing than the government-pay business as the commercial business is largely stagnant. While acknowledging that Cigna is behind the curve in terms of its reach within the government-pay space, he still believes the stock is poised to soar. “We view Cigna’s PBM segment earnings as not having significant short-term earnings risk and the company’s diversified earnings stream as undeserving of the steep discount applied to the shares in the wake of the Express Scripts merger,” he explained. As a result, the analyst initiated coverage with a Buy and set a $207 price target. The price target reflects his confidence in CI’s ability to surge 29% over the next twelve months.Wall Street seems to agree with Hill. CI has only been assigned Buy ratings in the last three months. Its average price target of $214 indicates 33% upside potential, falling just short of ANTM’s. Find Wall Street’s most loved stocks with the Top Analysts’ Stocks tool
Jefferies analyst Christopher Mandeville took a sneak-peek of Walmart’s first stand-alone health clinic and came back raving about the initiative.
EVP & CFO of Cvs Health Corp (30-Year Financial, Insider Trades) Eva C Boratto (insider trades) sold 8,130 shares of CVS on 09/12/2019 at an average price of $65 a share. Continue reading...
Pharmaceutical companies and middlemen known as pharmacy benefit managers are generally at odds in a battle over drug prices. So, who is actually responsible for high prescription prices?
Income in the bond market is rapidly disappearing, and that's a weird concept to try and wrap your head around.For decades -- centuries, even -- investors around the world have bought fixed-income instruments for relatively risk-free income. The concept is simple. You give money to a government or corporate entity who turns around and pays you interest for lending that money to compensate for risk and time.But this simple concept has been flipped on its head recently. Specifically, the "interest" part of the above fixed-income equation has gone out the window. Consider the following:InvestorPlace - Stock Market News, Stock Advice & Trading Tips * The 10-year Treasury yield is flirting with all-time lows around 1.8%. * The 30-year Treasury yield has plunged to all-time lows around 2.2%. * About one-third of tradeable bonds around the world now have negative yields, amounting to $17 trillion in negative-yielding debt. * The yield curves are entirely negative in countries like Germany, Denmark and the Netherlands.In other words, across the world, the income part of the fixed-income equation is rapidly disappearing. Weird, right?Despite this, U.S. equities are still giving investors income. That is, the S&P 500's dividend yield presently hovers around 2% -- significantly above all-time low levels (roughly 1% in 2000) and also on the upper end of where the S&P 500 dividend yield has hovered over the past 20 years.Big picture, then, while the fixed income market is suffering from disappearing income, stocks are still paying good income. * 7 Discount Retail Stocks to Buy for a Recession The implication? Buy stable dividend stocks which pay more than any other relatively risk-free bond in the world will. As investors grow tired of not even beating inflation by buying a 10-year Treasury note, they will inevitably pile into stocks which: 1) have much higher yields, and 2) have a history of steady and consistent dividend hikes.Without further ado, let's take a look at five dividend stocks that fit this description. Dividend Stocks to Buy: AT&T (T)Source: Jonathan Weiss / Shutterstock.com Dividend Yield: 5.3%Dividend History: The dividend has consistently increased over the past 34 years.At the top of this list, we have a stock which many consider the blue-chip dividend king: telecom giant AT&T (NYSE:T).AT&T has everything investors are looking for in a stable, income-paying stock. Big yield? Check. The stock yields 5.3%. History of dividend hikes? Check. AT&T has consistently hiked its dividend over the past three decades.Stable operations? Check. AT&T provides telecom services which U.S. consumers have become exceptionally dependent on -- indeed, the internet and wireless services which AT&T provides may be the most important utilities outside of water, food and electricity. Healthy catalysts on the horizon? Also, check. Next year, AT&T: 1) is launching new streaming services which should help offset cord-cutting weakness, and 2) will benefit from the mainstream and widespread deployment of 5G infrastructure and devices.AT&T stock is the quintessential stable dividend stock to buy at the current moment. American Electric Power (AEP)Source: Casimiro PT / Shutterstock.com Dividend Yield: 2.9%Dividend History: The dividend has consistently increased over the past six years.Next up, we have a utility giant that is best known for its stability and resiliency: electricity services provider American Electric Power (NYSE:AEP).Relative to other "big dividend stocks," AEP's yield isn't that big. It sits at just 2.9%. But, there are three things to note here. First, that 2.9% yield still smashes the 1.8% 10-year Treasury yield. Two, American Electric Power has a long track record of consistent dividend hikes that dates back at least six years, a stretch during which the dividend increased 100%. Three, American Electric Power has an equally long track record of consistent and stable revenue and profit growth, which has powered consistent gains in AEP stock over the past decade. * 10 Battered Tech Stocks to Buy Now As such, what AEP lacks in yield, it makes up for in operational consistency and stability. Consequently, the best way to look at AEP stock is as the best "stable" stock to buy. It just so happens to yield almost 3%, too, which is an added bonus. Qualcomm (QCOM)Source: JHVEPhoto / Shutterstock.com Dividend Yield: 3.1%Dividend History: The dividend has consistently increased over the past eight years.Third, we have a global chip giant that appears to be on the verge of finding its winning stride again -- Qualcomm (NASDAQ:QCOM).Unlike AT&T and American Electric Power, Qualcomm is not traditionally seen as an icon of stability. Just look at a five-year chart of QCOM stock to see why. But, most of the turbulence in QCOM stock over the past five years has been driven by operational noise -- namely, a big legal battle with their largest customer, Apple (NASDAQ:AAPL). That legal battle is now over, and it ended in a favorable outcome for Qualcomm.Consequently, looking in the rear-view mirror here is the wrong way to look at QCOM stock. It's not about what has happened. It's about what will happen. What will happen is good stuff. Qualcomm has locked in Apple as a customer for the next several years. At the same time, 5G phones are launching next year, and it appears pretty much every smartphone provider is leaning into Qualcomm to provide the infrastructure for those 5G phones. As such, Qualcomm will find itself as a big beneficiary of the 5G tailwind. This tailwind should last for several years, meaning that Qualcomm should be in winning stride for the foreseeable future.Ahead of the company regaining its winning stride, the stock still yields an impressive 3.1%. Thus, not only does QCOM stock have a compelling multi-year bull thesis, but the stock is also paying investors to buy into that compelling bull thesis. It's a win-win situation that ultimately gives QCOM the nod as a stable dividend stock to buy here and now. CVS (CVS)Source: Roman Tiraspolsky / Shutterstock.com Dividend Yield: 3.1%Dividend History: CVS last increased its dividend payout in 2017.Fourth, we have an undervalued, stable stock that is in the midst of a potentially huge breakout -- retail pharmacy giant CVS (NYSE:CVS).It's been a rough few years for CVS stock. On the retail pharmacy side, increased competition has simultaneously pressured current sales trends and depressed investor sentiment regarding future sales trends. On the pharmacy benefit manager side, legislation has similarly pressured sales and profits.Consequently, by mid-2019, CVS stock had dropped to $50 -- the stock's lowest level since early 2013 -- and was trading at under 8x forward earnings.Since then, retail sales trends have improved as CVS has refreshed stores and expanded omni-channel capabilities to overstep the competition. Such improvements should persist as the company expands a local healthcare program which has potential to dramatically improve core operational performance trends. At the same time, the White House has scrapped a bill which would've been disastrous for PBMs. And now the outlook on that side of the business is also improving significantly. * 10 Stocks to Sell in Market-Cursed September In response to these positive developments, CVS stock has rallied nearly 20% over the past three months. This rally is just getting started. The stock is still cheap, the yield is still big, the outlook is still improving and the upward momentum is very real. As such, CVS stock appears to be in the first few innings of a huge breakout. Target (TGT)Source: jejim / Shutterstock.com Yield: 2.4%Dividend History: The dividend has consistently increased over the past 51 years.Last, but not least, we have a blue-chip retail giant that is absolutely on fire today: Target (NYSE:TGT).The story at Target is pretty simple. A few years back, the mainstream emergence and adoption of e-commerce caused a traffic exodus out of Target stores. For a short period of time, Target struggled. Then, Target adapted. It built out a big e-commerce operation, refreshed stores to be more tech-savvy, built out omni-channel capabilities, expanded in-store and online offerings and much more.In a nutshell, Target became the quintessential, modern omni-channel retailer that leveraged technology to optimize customer convenience in every way possible.It worked. Over the past few years, Target has fired off its best numbers in a decade. We are talking decade-best sales growth, comparable sales growth, online sales growth and traffic growth. At the same time, margins have been largely stable, so profit growth has been equally robust. TGT stock has naturally rallied big in response to this operational excellence.This rally is far from over. Target has optimally positioned itself so that -- so long as the U.S. consumer remains healthy -- Target will continue to report impressive numbers. The stock isn't terribly expensive at all (17-times forward earnings), the yield remains big (2.4%) and TGT stock has very healthy upward momentum.TGT stock is a stable dividend stock which should stay in rally mode for the foreseeable future.As of this writing, Luke Lango was long T, QCOM, and CVS. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 5 Stable Dividend Stocks to Buy as Fixed Income Vanishes appeared first on InvestorPlace.
Panelists at our Trends & Innovations in Health Benefits event point to improvements in controlling the cost of care, but challenges on the horizon.
The sector has lagged behind the broader market, partly because of concern that the government could act to rein in drug prices.
We looked at the charts of CVS Health Corp. last week, but with Deutsche Bank recommending it today as its top pick we will visit it again this Thursday morning as it's the Real Money 'Stock of the Day'. In this daily bar chart of CVS, below, we can see that prices have crept higher the past week and trading volume looks like it has increased. The On-Balance-Volume (OBV) line has remained steady and the Moving Average Convergence Divergence (MACD) oscillator has moved to a new outright buy signal.
Analysts at Deutsche Bank call the company its 'top pick' in the managed care, drug supply and beneficiary technology space.
It's a rare moment when a losing call on volatile Rite Aid (NYSE:RAD) makes you a 28% profit. Let me explain: Back on Aug.7, I made a ridiculous statement that buying RAD stock for a short-term bet wasn't as crazy as initial looks might suggest. However, the markets made my bullishness look incredibly foolish very quickly.Source: Ken Wolter / Shutterstock.com Near mid-August, the embattled pharmacy retailer announced an executive shakeup. Former CEO John Standley stepped down from the top post. In his place came Heyward Donigan, who previously served as CEO for Sapphire Digital. During her time leading the company, she led the organization to record growth and consumer engagement.Under ordinary circumstances, Donigan would be a welcome lift to Rite Aid stock. After all, the once-powerful pharmacy retailer has massive competition. We're not just talking about peers, such as CVS Health (NYSE:CVS) or Walgreens Boots Alliance (NASDAQ:WBA). Instead, the RAD stock price is under pressure from disruptive names like Amazon (NASDAQ:AMZN).InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn that context, perhaps the fallout in shares wasn't surprising. When Rite Aid announced Donigan as CEO, the RAD stock price was hovering just above $7. Just a few days later, the equity hit a multi-year low of $5.27. With that, my speculative thesis blew up in my face. * 10 Stocks to Sell in Market-Cursed September But before the rounds of "I told you so's" could flood my inbox, Rite Aid stock started to turn around. From Aug. 27, the equity veritably skyrocketed, gaining nearly 75% to the close of Sept. 10. That made me look less foolish, for which I'm grateful.But what about RAD stock? Is there still an opportunity here after such a mercurial rise? Millennials Hold the Key to the RAD Stock PriceLike most market investments, the answer depends on millennials. As the largest generation in the workforce, this demographic essentially enjoys the China narrative: they're emerging as a true political and economic force, and there are a lot of them.Better yet, millennials bring many potential positives for Rite Aid stock and the broader pharmacy business. For one thing, their sheer numbers bring robust dollars into the mix. More significantly, 45% of millennials prefer using over-the-counter drugs versus depending on a doctor for a prescription.This is one stat for which Donigan and her team must focus on. She has a clear opportunity to convert visitors to sales.And they will come. Based on the Amazon Counter deal that I referenced in last month's story, this will incentivize a new breed of consumers to visit Rite Aid stores. I wrote that "Amazon shoppers are young, tech savvy, and make serious bank." This is exactly the type of demo that you need to get RAD stock out of its funk.Unfortunately, some bad news exists for Rite Aid stock as well. According to MarketingCharts.com, millennials are the most price-sensitive generation for consumer-packaged goods. For instance, millennials more so than any other generation are likely to buy over-the-counter meds on sale as opposed to their preferred brands.Obviously, the easy answer is to pump out some discounts to attract and secure millennial shoppers. But nothing associated with RAD stock is easy. Primarily, the company does not have the margins to play the discount game for a prolonged period.Therefore, Rite Aid stock is a race: can management attract and retain enough millennial shoppers to justify an initial cut to margins? This is not a believable route for many investors, and that's why they dumped shares. Right Now, It's About Tactics Over StrategyGiven the recent and dramatic changes in the RAD stock price, we have several ways to approach shares. First, if you made that 75% profit that I referenced earlier, congratulations! Now, it's time to dump out.Even if you made the smaller 28% profit, it's time to sell. Certainly, you don't want to get greedy with a volatile investment like Rite Aid stock.On the other hand, if you're approaching shares now, I'd wait. For starters, it's unlikely that RAD stock will continue to make double-digit jumps. Second, some stats, like the excessive institutional ownership worries me in this present context. If insiders panic, RAD will plummet faster than you can hit the "sell" button.Third, Rite Aid is scheduled to release their second quarter of fiscal 2020 earnings report near September end. I don't want to have excessive exposure here, especially since RAD stock can go anywhere following this report.But after that dust clears, the pharmacy giant might get interesting again. As I said, it really depends on whether Donigan can convert millennials. It's a herculean task, to be sure. But the opportunity is there, which represents the longer-term speculative case for Rite Aid stock.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post For Rite Aid Stock, Everything Depends on Millennials appeared first on InvestorPlace.